Grifols is anticipating a period of strong growth on the back of its recently FDA-approved intravenous immunoglobulin product Yimmugo ... has dropped the list of the next 15 drugs to be negotiated ...

Grifols SA engages in the production of plasma ... The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...